Australian Regulator Explains How To Comply With Advertising Rules While Meeting Continuous Disclosure Obligations
Companies should avoid focusing only on the positive qualities of a therapeutic good or omitting or downplaying the negative qualities such as possible side effects, according to new guidance on therapeutic goods advertising and Australian Securities Exchange announcements.
You may also be interested in...
BMS & Pfizer Win Funding ‘Firsts’ In England For Migraine & Heart Disease Drugs
Bristol Myers Squibb and Pfizer both asked the health technology assessment body NICE to evaluate their respective drugs, Camzyos and Vydura, for use in indications that are narrower than those for which they are – or will potentially be – approved.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add a new product – Tibsovo, Servier’s treatment for IDH1-mutated acute myeloid leukemia and IDH1-mutated cholangiocarcinoma.
Europe's Unitary Patent System Starts Up Today
The forthcoming unitary patent system and Unified Patent Court promise to make applying for patents in Europe and litigating infringements simpler and less costly for applicants.